4.7 Article

CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: results after 5-year follow-up

期刊

ANNALS OF THE RHEUMATIC DISEASES
卷 74, 期 8, 页码 1562-1566

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2014-206773

关键词

-

资金

  1. South-Eastern Norway Regional Health Authority [2011100]

向作者/读者索取更多资源

Objective To identify factors associated with elevated arterial stiffness in a 5-year follow-up of patients with ankylosing spondylitis (AS). Methods C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), Bath AS disease activity index (BASDAI) and AS disease activity score (ASDAS) were recorded in 2003, and arterial stiffness (Augmentation Index (AIx) and pulse wave velocity (PWV)) in 2008/2009. Patients were grouped into quartiles according to baseline CRP, ESR and BASDAI and four ASDAS groups. Trend analyses were performed using ANCOVA (AIx/PWV as dependent variable) with separate models for CRP, ESR, BASDAI and ASDAS (age and gender adjusted). Independent predictors of future AIx and PWV levels were identified in multivariate linear regression models. Results In total, 85 patients participated. Increasing baseline values of CRP, ESR and ASDAS were associated with elevated AIx on follow-up (p(trend) 0.01, 0.05 and 0.04, respectively). Similar non-significant patterns were seen for PWV. In the multivariate analyses, baseline CRP and ASDAS were independently associated with future elevated AIx (p=0.03 and 0.02, respectively). In the multivariate PWV model, results for CRP and ASDAS were non-significant. Conclusions Baseline CRP and ASDAS were associated with future elevated arterial stiffness measured as AIx, supporting that disease activity is related to future risk of cardiovascular disease in patients with AS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Rheumatology

Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment' by Felson et al

Ricardo J. O. Ferreira, Paco M. J. Welsing, Johannes W. G. Jacobs, Laure Gossec, Mwidimi Ndosi, Pedro M. Machado, Desiree van der Heijde, Jose A. P. Da Silva

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

Desiree van der Heijde, Atul Deodhar, Xenofon Baraliakos, Matthew A. Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut, Alicia M. Ellis, Carmen Fleurinck, Karl Gaffney, Lianne S. Gensler, Nigil Haroon, Marina Magrey, Walter P. Maksymowych, Alexander Marten, Ute Massow, Marga Oortgiesen, Denis Poddubnyy, Martin Rudwaleit, Julie Shepherd-Smith, Tetsuya Tomita, Filip van den Bosch, Thomas Vaux, Huji Xu

Summary: The BE MOBILE 1 and BE MOBILE 2 trials demonstrated that bimekizumab, a dual IL-17A and IL-17F inhibitor, improved efficacy outcomes in patients with axial spondyloarthritis (axSpA) and was well tolerated. These findings support the use of bimekizumab as a potential treatment option for axSpA.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Rheumatology

Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Andreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Robert B. M. Landewe

Summary: This study aimed to update the evidence on the efficacy of DMARDs and provide information for the 2022 update of EULAR recommendations for RA management. A systematic literature review was conducted to investigate the efficacy of cs, b, biosimilar, and tsDMARDs in RA patients. The results showed that csDMARDs combined with short-term glucocorticoids in early RA were as effective as bDMARD+MTX combination therapy. JAK inhibitors were effective in different patient populations. Tapering of DMARDs was feasible for some patients who could maintain low disease activity or achieve remission.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Rheumatology

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher J. Edwards, Patrick Verschueren, Savia de Souza, Janet Pope, Tsutomu Takeuchi, Kimme Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja Stamm, Jan W. Schoones, Robert B. M. Landewe

Summary: This study conducted a systematic literature review (SLR) to evaluate the safety of synthetic and biological disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA). The results indicated that bDMARDs were associated with an increased risk of serious infections compared to csDMARDs, while JAK inhibitors (JAKi) showed higher risk of herpes zoster infections. The risks of malignancies, major adverse cardiovascular events (MACE), and venous thromboembolism (VTE) were similar among different treatments.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Rheumatology

Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Sytske Anne Bergstra, Alexandre Sepriano, Andreas Kerschbaumer, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Josef S. Smolen, Robert B. M. Landewe

Summary: This systematic literature review examines the efficacy, duration of use, and safety of glucocorticoids (GCs) in the management of rheumatoid arthritis (RA). The study confirms the effectiveness of GCs in treating RA, with most patients able to stop GCs within 12-24 months. However, the use of GCs also carries well-known safety risks, including osteoporotic fractures, serious infections, diabetes, and mortality.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Pharmacology & Pharmacy

Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia

Vida Terzic, Lea Levoyer, Melanie Figarella, Elisabetta Bigagli, Noemie Mercier, Lucie De Gastines, Severine Gibowski, Marius Troseid, Jacques Demotes, Inge Christoffer Olsen, Maya Hites, Florence Ader, Jose Ramon Arribas Lopez, France Mentre, Helene Esperou, Dominique Costagliola, John-Arne Rottingen, Julien Poissy, Jean-Christophe Roze, Adilia Warris, Jackie O'Leary, Ricardo M. Fernandes, Lambert Assoumou, Regis Hankard, Mark A. Turner, Yazdan Yazdanpanah, Alpha Diallo

Summary: To ensure the safety of participants and regulatory compliance in academic trials, a centralized pharmacovigilance system was established, allowing sponsors to delegate work. This system consisted of key procedures, a local safety officer network, and centralized safety activities. Lessons learned from four trials demonstrated the ability to manage diverse European requirements and communicate effectively with trial teams.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Rheumatology

Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM

Sofia Ramiro, Robert Landewe, Desiree van der Heijde, Alexandre Sepriano, Oliver FitzGerald, Mikkel Ostergaard, Joanne Homik, Ori Elkayam, J. Carter Thorne, Maggie J. Larche, Gianfranco Ferraccioli, Marina Backhaus, Gilles Boire, Bernard Combe, Thierry Schaeverbeke, Alain Saraux, Maxime Dougados, Maurizio Rossini, Marcello Govoni, Luigi Sinigaglia, Alain G. Cantagrel, Cornelia F. Allaart, Cheryl Barnabe, Clifton O. Bingham III, Dirkjan van Schaardenburg, Hilde B. Hammer, Rana Dadashova, Edna Hutchings, Joel Paschke, Walter P. Maksymowych

Summary: The study investigates whether meticulously following a treat-to-target (T2T) strategy in daily clinical practice leads to less radiographic progression in patients with active rheumatoid arthritis (RA). The findings show that a more stringent application of T2T does not result in less radiographic progression compared to a somewhat lenient attitude towards T2T.

RHEUMATOLOGY (2023)

Article Medicine, General & Internal

Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden

Liv Cathrine Heggebo, Ida Maria Henriksen Borgen, Hillevi Rylander, Cecilie Kiserud, Tonje Haug Nordenmark, Taran Paulsen Hellebust, Morten Egeberg Evensen, Magnus Gustavsson, Christina Ramberg, Mette Sprauten, Henriette Magelssen, Hanne Blakstad, Janani Moorthy, Karin Andersson, Ingela Raunert, Thomas Henry, Cecilie Moe, Carin Granlund, Dorota Goplen, Jorunn Brekke, Tor-Christian Aase Johannessen, Tora Skeidsvoll Solheim, Kirsten Marienhagen, Oyvind Humberset, Per Bergstrom, Mans Agrup, Ludvig Dahl, Michael Gubanski, Helene Gojon, Carl-Johan Brahme, Isabelle Ryden, Asgeir S. Jakola, Einar O. Vik-Mo, Hanne C. Lie, Lars Asphaug, Maziar Hervani, Ingrid Kristensen, Corina Silvia Rueegg, Inge C. Olsen, Rolf J. Ledal, Eskil Degsell, Katja Werlenius, Malin Blomstrand, Petter Brandal

Summary: This study is an open-label, multicenter, randomized phase III non-inferiority study comparing proton therapy and photon therapy in the treatment of IDH-mutated diffuse gliomas grade 2-3. The results of this study will provide important information on the safety, cognition, fatigue, and quality of life parameters for this patient population.

BMJ OPEN (2023)

Article Rheumatology

Good construct validity of the CT Syndesmophyte Score (CTSS) in patients with radiographic axial spondyloarthritis

Rosalinde Stal, Sofia Ramiro, Xenofon Baraliakos, Juergen Braun, Monique Reijnierse, Rosaline van den Berg, Desiree van der Heijde, Floris A. van Gaalen

Summary: The objective of this study was to assess the construct validity of the CT Syndesmophyte Score (CTSS) for measuring structural spinal damage in patients with radiographic axial spondyloarthritis. The study compared the scores of CTSS and modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) in detecting syndesmophytes and their correlation with spinal mobility. The results demonstrated good agreement between CTSS and mSASSS in detecting syndesmophytes, and higher correlation of CTSS with spinal mobility measures.

RMD OPEN (2023)

Article Rheumatology

Inflammation, bone loss and 2-year bone formation at the same vertebra in axial spondyloarthritis: a multilevel MRI and low-dose CT analysis

Mary Lucy Marques, Nuno Pereira da Silva, Desiree van der Heijde, Rosalinde Stal, Xenofon Baraliakos, Juergen Braun, Monique Reijnierse, Caroline Bastiaenen, Sofia Ramiro, Floris A. van Gaalen

Summary: The study investigated the association between inflammation and lower trabecular bone density (TBD) in radiographic axial spondyloarthritis (r-axSpA), and whether a lower TBD increases the likelihood of 2-year bone formation at the same vertebra. The study found that inflammation was associated with lower TBD, but lower TBD itself did not increase the risk of new bone formation at the same vertebra.

RMD OPEN (2023)

Letter Biochemistry & Molecular Biology

The international Unity study for antivirals against mpox is a blueprint for future epidemics

Erica Telford, Beatriz Grinsztejn, Inge Christoffer Olsen, Nicolas Pulik, France Mentre, Skerdi Haviari, Maxime Hentzien, Olivier Segeral, Miquel B. Ekkelenkamp, Dimie Ogoina, Nathalie Strub-Wourgaft, Alpha Diallo, Yazdan Yazdanpanah, Alexandra Calmy

NATURE MEDICINE (2023)

Article Critical Care Medicine

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

Marius Troseid, Jose R. Arribas, Lambert Assoumou, Aleksander Rygh Holten, Julien Poissy, Vida Terzic, Fulvia Mazzaferri, Jesus Rodriguez Bano, Joe Eustace, Maya Hites, Michael Joannidis, Jose-Artur Paiva, Jean Reuter, Isabel Puentmann, Thale D. J. H. Patrick-Brown, Elin Westerheim, Katerina Nezvalova-Henriksen, Lydie Beniguel, Tuva Borresdatter Dahl, Maude Bouscambert, Monika Halanova, Zoltan Peterfi, Sotirios Tsiodras, Michael Rezek, Matthias Briel, Serhat Unal, Martin Schlegel, Florence Ader, Karine Lacombe, Cecilie Delphin Amdal, Serge Rodrigues, Kristian Tonby, Alexandre Gaudet, Lars Heggelund, Joy Mootien, Asgeir Johannessen, Jannicke Horjen Moller, Beatriz Diaz Pollan, Anders Aune Tveita, Anders Benjamin Kildal, Jean-Christophe Richard, Olav Dalgard, Victoria Charlotte Simensen, Aliou Balde, Lucie de Gastines, Marta del Alamo, Burc Aydin, Fridtjof Lund-Johansen, Mary-Anne Trabaud, Alpha Diallo, Bente Halvorsen, John-Arne Rottingen, Evelina Tacconelli, Yazdan Yazdanpanah, Inge C. Olsen, Dominique Costagliola

Summary: The study conducted a placebo-controlled trial of baricitinib in severe/critical COVID cases. The results showed that baricitinib did not reduce mortality within 60 days, and there may be safety risks in vaccinated participants, which require further investigation.

CRITICAL CARE (2023)

Review Critical Care Medicine

Effects of remdesivir in patients hospitalised with COVID-19 a systematic review and individual patient data meta- analysis of randomised controlled trials

Alain Amstutz, Benjamin Speich, France Mentre, Corina Silvia Rueegg, Drifa Belhadi, Lambert Assoumou, Charles Burdet, Srinivas Murthy, Lori Elizabeth Dodd, Yeming Wang, Kari A. O. Tikkinen, Florence Ader, Maya Hites, Maude Bouscambert, Mary Anne Trabaud, Mike Fralick, Todd C. Lee, Ruxandra Pinto, Andreas Barratt-Due, Fridtjof Lund-Johansen, Fredrik Mueller, Olli P. O. Nevalainen, Bin Cao, Tyler Bonnett, Alexandra Griessbach, Ala Taji Heravi, Christof Schonenberger, Perrine Janiaud, Laura Werlen, Soheila Aghlmandi, Stefan Schandelmaier, Yazdan Yazdanpanah, Dominique Costagliola, Inge Christoffer Olsen, Matthias Briel

Summary: This systematic review and meta-analysis assessed the benefits and harms of remdesivir compared to placebo or usual care in COVID-19 patients hospitalized. The study found that remdesivir reduced mortality in patients who required no or conventional oxygen support but did not have enough evidence for patients on ventilators.

LANCET RESPIRATORY MEDICINE (2023)

Letter Rheumatology

Subclinical inflammation and joint damage progression in patients with early RA fulfilling 2011 vs 2022 ACR/EULAR Boolean remission criteria: data from the ARCTIC study

Valeriia Melokhina, Nina Paulshus Sundlisaeter, Joseph Sexton, Ulf Sundin, Anna-Birgitte Aga, Kaja E. Kjorholt, Lena Bugge Nordberg, Desiree van der Heijde, Espen Haavardsholm, Siri Lillegraven

ANNALS OF THE RHEUMATIC DISEASES (2023)

暂无数据